Posts tagged NASDAQ:GTXI
Stifel nearly triples PT for GTx to $45 from $16

Stifel nearly tripled its price target for GTx (NASDAQ:GTXI) to $45 from $16 after the company reported significant positive new data at the SUFU Winter Meeting for its Phase 2 proof-of-concept study testing, enobosarm, in female patients with stress urinary incontinence (SUI). The stock closed at $16.81 on March 2.

Read More